Latest VIVIS LOI Potential First Step to Phase 1 Clinical Trial on Preventing COVID-19 Infections Using CBD

Author's Avatar
Sep 13, 2021

KATY, TX / ACCESSWIRE / September 13, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVID-19.